Wen-Lun Wang1, Yu-Chi Wang2, Ching-Tai Lee1, Chi-Yang Chang1, Jo-Lin Lo3, Yao-Hung Kuo4, Yao-Chun Hsu1, Lein-Ray Mo1. 1. Department of Internal Medicine, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan, China. 2. Department of Biological Science & Technology, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan, China. 3. Department of Oncology, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan, China. 4. Department of Radiation Oncology, E-Da Hospital/I-Shou University, Kaohsiung, Taiwan, China.
Abstract
OBJECTIVE: This study aimed to investigate the impact of human papillomavirus (HPV) infection on the prognosis and treatment response of esophageal squamous cell carcinoma (ESCC). METHODS: We examined the presence and subtypes of HPV in the tumors by polymerase chain reaction and sequencing in 150 ESCC patients. Their clinicopathological characteristics, treatment response and survival were further analyzed according to the presence of HPV infection. RESULTS: Of 150 ESCC tumor samples, 27 (18.0%) were HPV-positive, of which 22 (81.5%) had HPV-16 infection. The risk of developing multifocal ESCC was not significantly different in the HPV-positive and HPV-negative groups (29.6% vs 28.5%, P = 0.90). In subgroup analysis, patients with HPV-16-positive advanced ESCC had a significantly better survival than those with HPV-negative ESCC (3-year survival: 55% vs 21%, log-rank P = 0.03). Cox proportional hazards model showed that the presence of HPV-16 was associated with a significant reduction in the mortality rate (hazard ratio 0.41, 95% CI 0.18-0.96). Patients with HPV-16 infection had better response to chemoradiotherapy (CRT) than those without HPV-16 infection (P = 0.026). CONCLUSIONS: In patients with advanced ESCC, HPV-16-positive patients had a significantly favorable survival, especially those who received CRT. Larger scale studies are needed to determine the causal relationship.
OBJECTIVE: This study aimed to investigate the impact of human papillomavirus (HPV) infection on the prognosis and treatment response of esophageal squamous cell carcinoma (ESCC). METHODS: We examined the presence and subtypes of HPV in the tumors by polymerase chain reaction and sequencing in 150 ESCC patients. Their clinicopathological characteristics, treatment response and survival were further analyzed according to the presence of HPV infection. RESULTS: Of 150 ESCC tumor samples, 27 (18.0%) were HPV-positive, of which 22 (81.5%) had HPV-16 infection. The risk of developing multifocal ESCC was not significantly different in the HPV-positive and HPV-negative groups (29.6% vs 28.5%, P = 0.90). In subgroup analysis, patients with HPV-16-positive advanced ESCC had a significantly better survival than those with HPV-negative ESCC (3-year survival: 55% vs 21%, log-rank P = 0.03). Cox proportional hazards model showed that the presence of HPV-16 was associated with a significant reduction in the mortality rate (hazard ratio 0.41, 95% CI 0.18-0.96). Patients with HPV-16 infection had better response to chemoradiotherapy (CRT) than those without HPV-16 infection (P = 0.026). CONCLUSIONS: In patients with advanced ESCC, HPV-16-positive patients had a significantly favorable survival, especially those who received CRT. Larger scale studies are needed to determine the causal relationship.
Authors: Allini Mafra da Costa; José Humberto Tavares Guerreiro Fregnani; Paula Roberta Aguiar Pastrez; Vânia Sammartino Mariano; Estela Maria Silva; Cristovam Scapulatempo Neto; Denise Peixoto Guimarães; Luisa Lina Villa; Laura Sichero; Kari Juhani Syrjanen; Adhemar Longatto-Filho Journal: Infect Agent Cancer Date: 2017-10-13 Impact factor: 2.965
Authors: Laura Bognár; Ivett Hegedűs; Szabolcs Bellyei; Éva Pozsgai; László Zoltán; Katalin Gombos; Örs Péter Horváth; András Vereczkei; András Papp Journal: Infect Agent Cancer Date: 2018-11-29 Impact factor: 2.965